Search Results for "cutan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cutan. Results 41 to 50 of 99 total matches.
Naftifine For Fungal Skin Infections
The Medical Letter on Drugs and Therapeutics • Oct 21, 1988 (Issue 777)
and cutaneous candidiasis, and is also effective in pityriasis versicolor (PJ Haas et al,
Mykosen, 28:33, 1985 ...
Naftifine hydrochloride 1% cream (Naftin - Herbert Laboratories), was recently approved by the US Food and Drug Administration (FDA) for topical treatment of tinea cruris and tinea corporis. It is available only by prescription.
Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989 (Issue 802)
injection and other toxicity
is unusual, but acute pancreatitis and well-documented cutaneous eruptions ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
Docetaxel (Taxotere) for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Sep 27, 1996 (Issue 984)
, cutaneous reactions and anemia. Sensory and motor neuropathy
have been reported. Fluid retention, sometimes ...
Docetaxel (Taxotere - Rh ne-Poulenc Rorer), a semisynthetic taxoid similar to paclitaxel (Taxol - Medical Letter, 35:39, 1993), has been approved by the US Food and Drug Administration for use in locally advanced or metastatic breast cancer that has progressed or relapsed during treatment that included an anthracycline such as doxorubicin (Adriamycin, and others).
Topical Drugs for Aging Skin
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997 (Issue 1007)
Thorne in R
Marks, ed, Retinoids in Cutaneous Malignancy, Oxford:Blackwell, 1991, page 66).
Adverse ...
Topical tretinoin (all-trans-retinoic acid) has been used for years to treat skin damaged by chronic exposure to the sun (Medical Letter, 34:28, 1992). First approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin-A, and others), it has now been approved as an 0.05% formulation in an emollient cream base (Renova) for topical treatment of photodamaged skin. In recent years, alpha-hydroxy acids incorporated in some cosmetics have also been promoted as effective in improving the appearance of aging skin.
Ciclopirox (Penlac) Nail Lacquer for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000 (Issue 1080)
and cream (Loprox) for treatment of cutaneous fungal infection.
DRUGS FOR ONYCHOMYCOSIS — Dermatophyte ...
Ciclopirox nail lacquer (Penlac - Dermik) has been approved by the FDA for treatment of mild-to-moderate onychomycosis due to Trichophyton rubrum, without involvement of the lunula. The drug has been available for many years as a lotion and cream (Loprox) for treatment of cutaneous fungal infection
Omalizumab (Xolair) for Chronic Urticaria
The Medical Letter on Drugs and Therapeutics • May 27, 2013 (Issue 1417)
— Histamine release
from cutaneous mast cells causes urticaria and its
associated symptoms such as pruritus ...
Omalizumab (Xolair) is a recombinant humanized
monoclonal anti-IgE antibody currently approved by
the FDA for treatment of moderate to severe persistent
allergic asthma. It has been used off-label for treatment
of allergic rhinitis and food allergies. Recently the
results of a phase III clinical trial indicated that omalizumab
may be effective in treating chronic urticaria as
well.
Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
attributed to
copanlisib. Severe cutaneous reactions have also
been reported.
DRUG INTERACTIONS ...
The FDA has granted accelerated approval to copanlisib
(Aliqopa – Bayer), an intravenously administered
phosphatidylinositol 3-kinase (PI3K) inhibitor, for
treatment of adults with relapsed follicular lymphoma
who have received at least two prior systemic
therapies. Follicular lymphoma is a common subtype
of non-Hodgkin's lymphoma. Copanlisib is the second
PI3K inhibitor to be approved for this indication;
idelalisib (Zydelig), which is administered orally twice
daily, was the first.
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
2017; 11:22.
2. AL Nguyen et al. Real-life treatment of cutaneous warts with
cantharidin podophyllin ...
The FDA has approved cantharidin 0.7% solution
(Ycanth – Verrica) for topical treatment of molluscum
contagiosum in patients ≥2 years old. Ycanth
was the first drug to be approved in the US for this
indication. A 10.3% gel formulation of berdazimer
(Zelsuvmi), a nitric oxide-releasing agent, has
also been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9 doi:10.58347/tml.2024.1696b | Show Introduction Hide Introduction
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
, transient itching,
burning, stinging, and erythema, but they do not cause
cutaneous atrophy. Both drugs ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Prevention of Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
discontinuation of treatment. Adverse effects have included fever, cutaneous reactions
(erythroderma ...
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.